Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L. Mayer, Michael Gnant, Amylou C. Dueck et al.|The Lancet Oncology|2021Cited by 255
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trialJosé Manuel Pérez-García, Sofía Braga, Laia Garrigós et al.|Neuro-Oncology|2022Cited by 247
Predicting response and survival in chemotherapy-treated triple-negative breast cancerAleix Prat, Emilio Alba, Aňa Lluch et al.|British Journal of Cancer|2014Cited by 113